SCHEMBL24785334

SCHEMBL24785334

COc1cc(F)cc(-c2cnc(CO)nc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.41
▸ CYP1A1 P04798 3/20 0.40
▸ CYP1B1 Q16678 3/20 0.40
▸ GRK6 P43250 1/20 0.39
▸ FGFR1 P11362 2/20 0.37
▸ FGFR2 P21802 2/20 0.37
▸ LRRK2 Q5S007 2/20 0.37
▸ LDHA P00338 1/20 0.36
▸ GRIN1 Q05586 1/20 0.36
▸ GRIN2B Q13224 1/20 0.36
▸ PGR P06401 2/20 0.35
▸ ABCB1 P08183 3/20 0.35
▸ ABL1 P00519 1/20 0.35
▸ BCR P11274 1/20 0.35
▸ ABCC1 P33527 1/20 0.34
▸ ALKBH1 Q13686 1/20 0.34
▸ FGFR4 P22455 1/20 0.34
▸ FGFR3 P22607 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ CYP4F2 P78329 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30103004 1.00 KDM1A (0.41) KDM1ACYP1A1CYP1B1GRK6FGFR1
SCHEMBL24785335 0.84 KDM1A (0.41) KDM1ACYP1A1CYP1B1GRK6FGFR1
SCHEMBL25367489 0.81 KDM1A (0.41) KDM1ACYP1A1CYP1B1GRK6FGFR1
SCHEMBL30516658 0.81 KDM1A (0.41) KDM1ACYP1A1CYP1B1GRK6FGFR1
SCHEMBL24784608 0.77 KDM1A (0.40) KDM1ACYP1A1CYP1B1GRK6FGFR1
SCHEMBL30018135 0.75 CYP1A1 (0.55) KDM1ACYP1A1CYP1B1GRK6LRRK2
SCHEMBL27859257 0.75 CYP1A1 (0.55) KDM1ACYP1A1CYP1B1GRK6LRRK2
SCHEMBL30103132 0.75 KDM1A (0.47) KDM1ACYP1A1CYP1B1GRK6FGFR1
SCHEMBL24785377 0.75 KDM1A (0.47) KDM1ACYP1A1CYP1B1GRK6FGFR1
SCHEMBL26784179 0.74 ABL1 (0.49) PGRABCB1ABL1BCRCYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022257960-A1 BICYCLIC COMPOUND FOR THE TREATMENT OF EP2 AND EP4 RECEPTOR-MEDIATED DISEASES 武汉人福创新药物研发中心有限公司 2022-12-15 — — WO disclosed
Send feedback